Sharing Progress in Cancer Care (SPCC) posted on LinkedIn:
“HER2-positive breast cancer remains one of oncology’s most complex challenges.
But recent advances in diagnostics are opening the way for truly personalised treatment strategies.
Join us for a live webinar and explore how the Definitive Trial is shaping the future of early-stage HER2-positive breast cancer care:
– Using the HER2DX® diagnostic assay to guide treatment decisions
– Improving patients’ quality of life without compromising outcomes or survival
– Demonstrating safety, efficiency, and potential cost reductions for healthcare systems
Date: Tuesday, 28 October 2025 | 18:00 CET
Speakers: Esther Sanfeliu (ES), Mattia Rediti (IT), Aleksandra Filipovic MD Ph.D. (UK)
The DEFINITIVE consortium brings together 18 partners from 7 countries, ensuring multidisciplinary expertise and European coverage.
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA.
Neither the European Union nor the granting authority can be held responsible for them.
This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).”
Read more posts about Breast Cancer on OncoDaily.